Study 8 of 721 for search of: "Gastroenteritis"
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department
This study is ongoing, but not recruiting participants.
Sponsors and Collaborators: The Hospital for Sick Children
National Center for Research Resources (NCRR)
GlaxoSmithKline
Children's Memorial Hospital
Information provided by: The Hospital for Sick Children
ClinicalTrials.gov Identifier: NCT00120744
  Purpose

The objectives of the study were to determine whether ondansetron treatment would reduce:

  • the amount of vomiting in the emergency department;
  • the need for intravenous rehydration; and
  • the need for hospitalization.

Condition Intervention
Gastroenteritis
Vomiting
Diarrhea
Dehydration
Drug: Ondansetron Oral Disintegrating Tablet

MedlinePlus related topics: Diarrhea Gastroenteritis Nausea and Vomiting
Drug Information available for: Ondansetron Ondansetron hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Randomized Trial of the Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Acute Gastroenteritis in a Pediatric Emergency Department

Further study details as provided by The Hospital for Sick Children:

Primary Outcome Measures:
  • The proportion of children who vomit during oral rehydration therapy after receiving either 0.13-0.27 mg per kilogram of an oral disintegrating ondansetron tablet or placebo.

Secondary Outcome Measures:
  • To compare in each treatment arm: mean number of episodes of vomiting, the proportion of children administered supplemental intravenous rehydration or requiring hospitalization.

Study Start Date: January 2004
Estimated Study Completion Date: April 2005
Detailed Description:

Background:

Vomiting may limit the success of oral rehydration in children with gastroenteritis and dehydration. Limited data suggest that while oral ondansetron may reduce vomiting from gastroenteritis, emergency department revisits may increase.

Methods:

The investigators conducted a prospective, double-blind randomized trial at a pediatric emergency department in 214 dehydrated children, aged 6 months to 10 years with gastroenteritis and mild to moderate dehydration as assessed by a dehydration score. They were randomly assigned to receive treatment with an ondansetron oral disintegrating tablet or placebo. Oral rehydration was administered according to a standard protocol. The primary outcome was the proportion of children who vomited during oral rehydration therapy. The secondary outcomes were the mean number of episodes of vomiting, and the proportion of children treated with intravenous rehydration or hospitalized.

  Eligibility

Ages Eligible for Study:   6 Months to 10 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Acute gastroenteritis
  • Non-bilious and non-bloody vomiting within 4 hours of triage
  • Diarrhea
  • Mild to moderate dehydration

Exclusion Criteria:

  • Weight less than 8 kilograms
  • Severe dehydration
  • Underlying disease which might affect the assessment of hydration status (e.g., chronic renal failure, hypoalbuminemia, congestive heart failure, on diuretics)
  • History of abdominal surgery
  • Hypersensitivity to the drug or any components in its formulation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00120744

Sponsors and Collaborators
The Hospital for Sick Children
GlaxoSmithKline
Children's Memorial Hospital
Investigators
Principal Investigator: Stephen B Freedman, MDCM, MSCI The Hospital for Sick Children
  More Information

Study ID Numbers: 2003-12038
Study First Received: July 12, 2005
Last Updated: September 7, 2006
ClinicalTrials.gov Identifier: NCT00120744  
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Diarrhea
Vomiting
Metabolic Diseases
Signs and Symptoms, Digestive
Gastrointestinal Diseases
Serotonin
Signs and Symptoms
Digestive System Diseases
Emergencies
Water-Electrolyte Imbalance
Ondansetron
Gastroenteritis
Metabolic disorder
Dehydration

Additional relevant MeSH terms:
Neurotransmitter Agents
Disease Attributes
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Gastrointestinal Agents
Central Nervous System Depressants
Antiemetics
Antipsychotic Agents
Pharmacologic Actions
Serotonin Antagonists
Serotonin Agents
Pathologic Processes
Autonomic Agents
Therapeutic Uses
Antipruritics
Anti-Anxiety Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Dermatologic Agents

ClinicalTrials.gov processed this record on January 16, 2009